Federal Circuit reverses Section 101 invalidation of life science patent
The Federal Circuit has ruled that the claims of a patent for liver cell treatment were not directed to a patent-ineligible concept, in a decision that provides guidance on how life science innovations can satisfy the Mayo test
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
